We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bristol Myers Squibb’s Targets Earlier Use of Its CAR-T Therapy
Bristol Myers Squibb’s Targets Earlier Use of Its CAR-T Therapy
Bristol Myers Squibb (BMS) is evaluating its CAR-T therapy Breyanzi for use during earlier lines of therapy for adult lymphoma patients and said early treatment significantly improved patient outcomes in a late-stage trial.